Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Adial Pharmaceuticals ( (ADIL) ) has shared an announcement.
Adial Pharmaceuticals has extended its CEO Cary Claiborne’s tenure with a new three-year employment agreement effective from December 5, 2024. The revised terms include a higher bonus target, set at 50% of Claiborne’s base salary contingent on meeting specific objectives, and stock options for 350,000 shares under the company’s equity plan, vesting over 36 months.
See more insights into ADIL stock on TipRanks’ Stock Analysis page.